Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENTR 601 50

Next Previous
Drug Profile

ENTR 601 50

Alternative Names: ENTR-601-50

Latest Information Update: 19 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Entrada Therapeutics
  • Class Drug conjugates; Oligonucleotides
  • Mechanism of Action Dystrophin expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 09 Jan 2026 MHRA and Research Ethics Committee approves IND application for ENTR 601 50 in Duchenne muscular dystrophy
  • 17 Nov 2025 Entrada Therapeutics plans to initiate phase I/II ELEVATE-50-201 trial for Duchenne muscular dystrophy in the United Kingdom (Parenteral)
  • 07 Nov 2025 Entrada Therapeutics filed for regulatory authorization in U.K. to initiate phase I/II ELEVATE-50-201 trial

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top